BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 33655199)

  • 1. Droplet Digital PCR Improves IG-/TR-based MRD Risk Definition in Childhood B-cell Precursor Acute Lymphoblastic Leukemia.
    Della Starza I; Nunes V; Lovisa F; Silvestri D; Cavalli M; Garofalo A; Campeggio M; De Novi LA; Soscia R; Oggioni C; Mussolin L; Biondi A; Guarini A; Valsecchi MG; Conter V; Biffi A; Basso G; Foà R; Cazzaniga G
    Hemasphere; 2021 Mar; 5(3):e543. PubMed ID: 33655199
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Digital Droplet PCR Is a Reliable Tool to Improve Minimal Residual Disease Stratification in Adult Philadelphia-Negative Acute Lymphoblastic Leukemia.
    Della Starza I; De Novi LA; Santoro A; Salemi D; Spinelli O; Tosi M; Soscia R; Paoloni F; Cappelli LV; Cavalli M; Apicella V; Bellomarino V; Di Lello E; Vitale A; Vignetti M; Fabbiano F; Rambaldi A; Bassan R; Guarini A; Chiaretti S; Foà R
    J Mol Diagn; 2022 Aug; 24(8):893-900. PubMed ID: 35710027
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Optimization of PCR-based minimal residual disease diagnostics for childhood acute lymphoblastic leukemia in a multi-center setting.
    van der Velden VH; Panzer-Grümayer ER; Cazzaniga G; Flohr T; Sutton R; Schrauder A; Basso G; Schrappe M; Wijkhuijs JM; Konrad M; Bartram CR; Masera G; Biondi A; van Dongen JJ
    Leukemia; 2007 Apr; 21(4):706-13. PubMed ID: 17287857
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Early T-cell precursor acute lymphoblastic leukaemia in children treated in AIEOP centres with AIEOP-BFM protocols: a retrospective analysis.
    Conter V; Valsecchi MG; Buldini B; Parasole R; Locatelli F; Colombini A; Rizzari C; Putti MC; Barisone E; Lo Nigro L; Santoro N; Ziino O; Pession A; Testi AM; Micalizzi C; Casale F; Pierani P; Cesaro S; Cellini M; Silvestri D; Cazzaniga G; Biondi A; Basso G
    Lancet Haematol; 2016 Feb; 3(2):e80-6. PubMed ID: 26853647
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Transferring measurable residual disease measurement in pediatric acute lymphoblastic leukemia from quantitative real-time PCR to digital droplet PCR.
    Luib L; Kreyenberg H; Michaelis S; Handgretinger R; Mezger M
    Pediatr Transplant; 2023 Jun; 27(4):e14483. PubMed ID: 36750990
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Minimal residual disease is an important predictive factor of outcome in children with relapsed 'high-risk' acute lymphoblastic leukemia.
    Paganin M; Zecca M; Fabbri G; Polato K; Biondi A; Rizzari C; Locatelli F; Basso G
    Leukemia; 2008 Dec; 22(12):2193-200. PubMed ID: 18754029
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Flow-cytometric minimal residual disease monitoring in blood predicts relapse risk in pediatric B-cell precursor acute lymphoblastic leukemia in trial AIEOP-BFM-ALL 2000.
    Schumich A; Maurer-Granofszky M; Attarbaschi A; Pötschger U; Buldini B; Gaipa G; Karawajew L; Printz D; Ratei R; Conter V; Schrappe M; Mann G; Basso G; Dworzak MN;
    Pediatr Blood Cancer; 2019 May; 66(5):e27590. PubMed ID: 30561169
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Molecular response to treatment redefines all prognostic factors in children and adolescents with B-cell precursor acute lymphoblastic leukemia: results in 3184 patients of the AIEOP-BFM ALL 2000 study.
    Conter V; Bartram CR; Valsecchi MG; Schrauder A; Panzer-Grümayer R; Möricke A; Aricò M; Zimmermann M; Mann G; De Rossi G; Stanulla M; Locatelli F; Basso G; Niggli F; Barisone E; Henze G; Ludwig WD; Haas OA; Cazzaniga G; Koehler R; Silvestri D; Bradtke J; Parasole R; Beier R; van Dongen JJ; Biondi A; Schrappe M
    Blood; 2010 Apr; 115(16):3206-14. PubMed ID: 20154213
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Molecular detection of minimal residual disease is a strong predictive factor of relapse in childhood B-lineage acute lymphoblastic leukemia with medium risk features. A case control study of the International BFM study group.
    Biondi A; Valsecchi MG; Seriu T; D'Aniello E; Willemse MJ; Fasching K; Pannunzio A; Gadner H; Schrappe M; Kamps WA; Bartram CR; van Dongen JJ; Panzer-Grümayer ER
    Leukemia; 2000 Nov; 14(11):1939-43. PubMed ID: 11069029
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Minimal residual disease-directed risk stratification using real-time quantitative PCR analysis of immunoglobulin and T-cell receptor gene rearrangements in the international multicenter trial AIEOP-BFM ALL 2000 for childhood acute lymphoblastic leukemia.
    Flohr T; Schrauder A; Cazzaniga G; Panzer-Grümayer R; van der Velden V; Fischer S; Stanulla M; Basso G; Niggli FK; Schäfer BW; Sutton R; Koehler R; Zimmermann M; Valsecchi MG; Gadner H; Masera G; Schrappe M; van Dongen JJ; Biondi A; Bartram CR;
    Leukemia; 2008 Apr; 22(4):771-82. PubMed ID: 18239620
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Postinduction minimal residual disease monitoring by polymerase chain reaction in children with acute lymphoblastic leukemia.
    Paganin M; Fabbri G; Conter V; Barisone E; Polato K; Cazzaniga G; Giraldi E; Fagioli F; Aricò M; Valsecchi MG; Basso G
    J Clin Oncol; 2014 Nov; 32(31):3553-8. PubMed ID: 25287825
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Applicability of droplet digital polymerase chain reaction for minimal residual disease monitoring in Philadelphia-positive acute lymphoblastic leukaemia.
    Ansuinelli M; Della Starza I; Lauretti A; Elia L; Siravo V; Messina M; De Novi LA; Taherinasab A; Canichella M; Guarini A; Foà R; Chiaretti S
    Hematol Oncol; 2021 Dec; 39(5):680-686. PubMed ID: 34402088
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Minimal Residual Disease in Acute Lymphoblastic Leukemia: Technical and Clinical Advances.
    Della Starza I; Chiaretti S; De Propris MS; Elia L; Cavalli M; De Novi LA; Soscia R; Messina M; Vitale A; Guarini A; Foà R
    Front Oncol; 2019; 9():726. PubMed ID: 31448230
    [No Abstract]   [Full Text] [Related]  

  • 14. FLT3-ITD in Children with Early T-cell Precursor (ETP) Acute Lymphoblastic Leukemia: Incidence and Potential Target for Monitoring Minimal Residual Disease (MRD).
    Lo Nigro L; Andriano N; Buldini B; Silvestri D; Villa T; Locatelli F; Parasole R; Barisone E; Testi AM; Biondi A; Valsecchi MG; Rizzari C; Conter V; Basso G; Cazzaniga G
    Cancers (Basel); 2022 May; 14(10):. PubMed ID: 35626079
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Late MRD response determines relapse risk overall and in subsets of childhood T-cell ALL: results of the AIEOP-BFM-ALL 2000 study.
    Schrappe M; Valsecchi MG; Bartram CR; Schrauder A; Panzer-Grümayer R; Möricke A; Parasole R; Zimmermann M; Dworzak M; Buldini B; Reiter A; Basso G; Klingebiel T; Messina C; Ratei R; Cazzaniga G; Koehler R; Locatelli F; Schäfer BW; Aricò M; Welte K; van Dongen JJ; Gadner H; Biondi A; Conter V
    Blood; 2011 Aug; 118(8):2077-84. PubMed ID: 21719599
    [TBL] [Abstract][Full Text] [Related]  

  • 16. MRD Detection in B-Cell Non-Hodgkin Lymphomas Using Ig Gene Rearrangements and Chromosomal Translocations as Targets for Real-Time Quantitative PCR.
    Pott C; Brüggemann M; Ritgen M; van der Velden VHJ; van Dongen JJM; Kneba M
    Methods Mol Biol; 2019; 1956():199-228. PubMed ID: 30779036
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Risk of relapse of childhood acute lymphoblastic leukemia is predicted by flow cytometric measurement of residual disease on day 15 bone marrow.
    Basso G; Veltroni M; Valsecchi MG; Dworzak MN; Ratei R; Silvestri D; Benetello A; Buldini B; Maglia O; Masera G; Conter V; Arico M; Biondi A; Gaipa G
    J Clin Oncol; 2009 Nov; 27(31):5168-74. PubMed ID: 19805690
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Minimal residual disease detection by mutation-specific droplet digital PCR for leukemia/lymphoma.
    Shirai R; Osumi T; Keino D; Nakabayashi K; Uchiyama T; Sekiguchi M; Hiwatari M; Yoshida M; Yoshida K; Yamada Y; Tomizawa D; Takae S; Kiyokawa N; Matsumoto K; Yoshioka T; Hata K; Hori T; Suzuki N; Kato M
    Int J Hematol; 2023 Jun; 117(6):910-918. PubMed ID: 36867356
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prospective use of molecular minimal residual disease for risk stratification in children and adolescents with acute lymphoblastic leukemia : Long-term results of the AIEOP-BFM ALL 2000 trial in Austria.
    Ronceray L; Dworzak M; Dieckmann K; Ebetsberger-Dachs G; Glogova E; Haas OA; Jones N; Nebral K; Moser R; Lion T; Meister B; Panzer-Grümayer R; Strehl S; Peters C; Pötschger U; Urban C; Mann G; Attarbaschi A;
    Wien Klin Wochenschr; 2023 Aug; ():. PubMed ID: 37535134
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparative analysis between RQ-PCR and digital-droplet-PCR of immunoglobulin/T-cell receptor gene rearrangements to monitor minimal residual disease in acute lymphoblastic leukaemia.
    Della Starza I; Nunes V; Cavalli M; De Novi LA; Ilari C; Apicella V; Vitale A; Testi AM; Del Giudice I; Chiaretti S; Foà R; Guarini A
    Br J Haematol; 2016 Aug; 174(4):541-9. PubMed ID: 27172403
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.